There were no serious B-RTO-related
complications. Subjects experienced fever, mild abdominal distress and hemoglobinuria, but all of these symptoms subsided with conservative treatment within a week. There were no significant changes in the total bilirubin levels for the SRS (−) and B-RTO groups. When the total bilirubin levels at the start of the study (baseline, month 0) were compared at various measurement times in the SRS (+) group, the total bilirubin levels slowly worsened with time: 12 months (1.13 ± 0.09 Selleckchem Nutlin 3 vs 1.42 ± 0.18 mg/dl; P < 0.05), 24 months (1.13 ± 0.09 vs 1.52 ± 0.19 mg/dl; P < 0.05), and 36 months (1.13 ± 0.09 vs 2.33 ± 0.38 mg/dl: P < 0.05). When the bilirubin levels were compared among the three groups at 36 months, a significant difference was found between the SRS (−) and SRS (+) groups (1.35 ± 0.17 vs 2.33 ± 0.38 mg/dl, respectively; P < 0.05) (Fig. 2).
When the albumin levels at baseline were compared at various measurement times, the albumin levels were significantly elevated in the B-RTO group at 6 months (3.44 ± 0.09 vs 3.65 ± 0.10 mg/dl; P < 0.05) and 12 months (3.44 ± 0.09 vs 3.66 ± 0.09 mg/dl: P < 0.05). In contrast, the albumin levels decreased in the SRS (−) and SRS (+) groups at 24 months (SRS (−) group: 3.58 ± 0.08 vs 3.41 ± 0.09 mg/dl; P < 0.05 and SRS (+) group: Small molecule library purchase 3.58 ± 0.08 vs 3.30 ± 0.09 mg/dl; P < 0.05) and at 36 months (SRS (−) group: 3.58 ± 0.08 vs 3.34 ± 0.10 mg/dl: P < 0.05 and SRS (+) group: 3.58 ± 0.08 vs 3.18 ± 0.11 mg/dl: P < 0.05). There were no significant differences in the albumin levels among the three groups (Fig. 3). There were no significant changes in the prothrombin times for the SRS (−) and B-RTO groups. The prothrombin times were decreased for the SRS (+) group compared with the baseline values: 36 months (74.06 ± 2.30 vs 63.71 ± 2.96%; P < 0.05). There were no significant differences
in the prothrombin times among the three groups (Fig. 4). The B-RTO group showed a significant improvement in the Child–Pugh score at 6 months compared with the baseline score (6.10 ± 0.20 vs 5.50 ± 0.17; P < 0.05). The score significantly worsened for the SRS (−) group at 36 months 上海皓元医药股份有限公司 compared with baseline (5.89 ± 0.23 vs 6.50 ± 0.31; P < 0.05). The score worsened for the SRS (+) group at 12 months (5.85 ± 0.15 vs 6.45 ± 0.28; P < 0.05), 24 months (5.85 ± 0.15 vs 6.65 ± 0.26; P < 0.05), and 36 months (5.85 ± 0.15 vs 7.93 ± 0.54; P < 0.05). There were significant differences among the three groups at 36 months: between the SRS (+) and SRS (−) groups and between the SRS (+) and B-RTO groups (7.93 ± 0.54 vs 6.50 ± 0.31, 6.43 ± 0.36; P < 0.05) (Fig. 5). Encephalopathy and ascites were not seen in any of the groups in the period 0–36 months.